Grant: Applied Research and Development Grants - Level 3
C.E.G.E.P. Lévis-Lauzon
$125,000.00
Optimization of topical formulations for the treatment of basal cell carcinoma using the Feldan Shuttle technology
FY 2020-21
Summary
This ARD proposal aims at validating the efficiency of new proprietary drug formulations for the treatment of skin cancers. In this research project, a preclinical model will be used and validated to demonstrate the efficacy of the formulation as well as its superiority compared to non-formulated treatment. This project will strongly support the supporting partner by addressing technical questions in the context of skin-applied treatments that will enhance significantly their portfolio to support their economic growth and target markets. Moreover, these formulations may provide significant improvement for patients having basal cell carcinoma or the genetic syndrome termed Gorlin Syndrome where recurrent tumoral lesions are occurring leading to problematic need for serial surgery or systemic treatment with adverse effects.
_x000d_Cette demande de projet RDA vise à valider l'efficacité de nouvelles formulations pour le traitement des cancers de la peau. Dans ce projet de recherche, un modèle préclinique sera utilisé et validé pour démontrer l'efficacité de la formulation ainsi que
Program
Applied Research and Development Grants - Level 3
Recipient
Location
Quebec, Canada
Type
Grant
Source
NSERC's Awards Data
As published
Application id
549971-2020
Name nom
Fortier, Isabelle
Department département
Siège social
Organization id
21757
Institution établissement
C.E.G.E.P. Lévis-Lauzon
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
125000
Program id
CARD3
Program name en
Applied Research and Development Grants - Level 3
Program name fr
Subventions de recherche et développement appliquée - niveau 3
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1561
Committee name en
Applied Research and Development Grants
Committee name fr
Subventions de recherche et développement appliquée
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
6404
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pharmacology
Research subject fr
Pharmacologie
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Optimization of topical formulations for the treatment of basal cell carcinoma using the Feldan Shuttle technology
Keyword
NSERC
Application summary
This ARD proposal aims at validating the efficiency of new proprietary drug formulations for the treatment of skin cancers. In this research project, a preclinical model will be used and validated to demonstrate the efficacy of the formulation as well as its superiority compared to non-formulated treatment. This project will strongly support the supporting partner by addressing technical questions in the context of skin-applied treatments that will enhance significantly their portfolio to support their economic growth and target markets. Moreover, these formulations may provide significant improvement for patients having basal cell carcinoma or the genetic syndrome termed Gorlin Syndrome where recurrent tumoral lesions are occurring leading to problematic need for serial surgery or systemic treatment with adverse effects.
_x000d_Cette demande de projet RDA vise à valider l'efficacité de nouvelles formulations pour le traitement des cancers de la peau. Dans ce projet de recherche, un modèle préclinique sera utilisé et validé pour démontrer l'efficacité de la formulation ainsi que
